Citations

Clear

2285 citation(s) found for "Yu, Anthony".

16S rRNA Gene PCR/Sequencing of Cerebrospinal Fluid in the Diagnosis of Post-operative Meningitis
Ramakrishna, Jahanavi M. , Libertin, Claudia R. , Yang, Joshua N., Diaz, Mark Anthony , Nengue, Anne L., Patel, Robin , Diaz, Mark A, Patel, Robin , Libertin, Claudia

Mayo Clinic

Access Microbiology | February 3, 2020 | Volume: 2 | Issue: 2 | Pages: No page available

10.1099/acmi.0.000100 | PMID 34568757 Get It

Introduction. Post-operative meningitis (POM) is a life-threatening complication of neurosurgery. Diagnosis is often difficult due to pre-existing inflammation and antecedent antimicrobial use. Bacterial cerebrospinal fluid (CSF) cultures may reveal no growth, but empiric antibiotics are typically given due to the high morbidity and mortality associated with POM. 16S rRNA gene PCR/sequencing is a molecular methodology that can identify the presence of bacteria regardless of viability for culture. Case Presentation. A patient presented with a rapid onset of fever associated with headache, neck pain, nausea and altered mental status 11 days after undergoing laser interstitial thermal therapy for treatment of recurrent astrocytoma at another hospital. Based on clinical presentation and imaging, POM was suspected, and empiric antibacterial therapy was started. Microbiological stains and cultures of CSF were negative. Due to persistent fevers, 16S rRNA gene PCR/sequencing was done on CSF; it detected a member of the order Enterobacteriales most closely resembling Serratia species. All antimicrobials were stopped except for cefepime, which was given for 2 weeks. The patient’s mental status fully recovered. Conclusion. The application of 16S rRNA gene PCR/sequencing in the setting of POM is of value by improving the quality of patient care and decreasing costs by antimicrobial de-escalation. Further studies regarding the positive and negative predictive values of this test are required.
Antithrombotic effects of heme-degrading and heme-binding proteins
Nath, Karl A. , Grande, Joseph P. , Belcher, John D. , Croatt, Anthony J., Hillestad, Matthew L. , Barry, Michael A. , Nath, Meryl C. , Regan, Raymond F. , Vercellotti, Gregory M. , Barry, Michael A , Garovic, Vesna D.

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | January 31, 2020 | Volume: 318 | Issue: 3 | Pages: H671-H681

10.1152/ajpheart.00280.2019 | PMID 32004074 Get It

In the murine venous thrombosis model induced by ligation of the inferior vena cava (IVCL), genetic deficiency of heme oxygenase-1 (HO-1) increases clot size. This study examined whether induction of HO-1 or administration of its products reduces thrombosis. Venous HO-1 upregulation by gene delivery reduced clot size, as did products of HO activity, biliverdin, and carbon monoxide. Induction of HO-1 by hemin reduced clot formation, clot size, and upregulation of plasminogen activator inhibitor-1 (PAI-1) that occurs in the IVCL model, while leaving urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA) expression unaltered. The reductive effect of hemin on clot size required HO activity. The IVCL model exhibited relatively high concentrations of heme that peaked just before maximum clot size, then declined as clot size decreased. Administration of hemin decreased heme concentration in the IVCL model. HO-2 mRNA was induced twofold in the IVCL model (vs. 40-fold HO-1 induction), but clot size was not increased in HO-2 −/− mice compared with HO-2 +/+ mice. Hemopexin, the major heme-binding protein, was induced in the IVCL model, and clot size was increased in hemopexin −/− mice compared with hemopexin +/+ mice. We conclude that in the IVCL model, the heme-degrading protein HO-1 and HO products inhibit thrombus formation, as does the heme-binding protein, hemopexin. The reductive effects of hemin administration require HO activity and are mediated, in part, by reducing PAI-1 upregulation in the IVCL model. We speculate that HO-1, HO, and hemopexin reduce clot size by restraining the increase in clot concentration of heme (now recognized as a procoagulant) that otherwise occurs. NEW & NOTEWORTHY This study provides conclusive evidence that two proteins, one heme-degrading and the other heme-binding, inhibit clot formation. This may serve as a new therapeutic strategy in preventing and treating venous thromboembolic disease.
Cardiac sympathetic denervation and synucleinopathy in Alzheimer’s disease with brain Lewy body disease
Callan, Michael, Cutler, Brett, Glass, Michael J. , Walker, Jessica E. , Intorcia, Anthony J., Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Belden, Christine M. , Zamrini, Edward , Sue, Lucia I., Vargas, Daisy, Beach, Thomas G. , Driver-Dunckley, Erika, Serrano, Geidy E. , Shprecher, David , Zhang, Nan , Adler, Charles H.

Mayo Clinic

Brain Communications | January 28, 2020 | Volume: 2 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcaa004 | PMID 32064463 Get It

Abstract Comorbid Lewy body pathology is very common in Alzheimer’s disease and may confound clinical trial design, yet there is no in vivo test to identify patients with this. Tissue (and/or radioligand imaging) studies have shown cardiac sympathetic denervation in Parkinson’s disease and dementia with Lewy bodies, but this has not been explored in Alzheimer’s subjects with Lewy bodies not meeting dementia with Lewy bodies clinicopathological criteria. To determine if Alzheimer’s disease with Lewy bodies subjects show sympathetic cardiac denervation, we analysed epicardial and myocardial tissue from autopsy-confirmed cases using tyrosine hydroxylase and neurofilament immunostaining. Comparison of tyrosine hydroxylase fibre density in 19 subjects with Alzheimer’s disease/dementia with Lewy bodies, 20 Alzheimer’s disease with Lewy bodies, 12 Alzheimer’s disease subjects without Lewy body disease, 19 Parkinson’s disease, 30 incidental Lewy body disease and 22 cognitively normal without Alzheimer’s disease or Lewy body disease indicated a significant group difference (P < 0.01; Kruskal–Wallis analysis of variance) and subsequent pair-wise Mann–Whitney U tests showed that Parkinson’s disease (P < 0.05) and Alzheimer’s disease/dementia with Lewy bodies (P < 0.01) subjects, but not Alzheimer’s disease with Lewy bodies subjects, had significantly reduced tyrosine hydroxylase fibre density as compared with cognitively normal. Both Parkinson’s disease and Alzheimer’s disease/dementia with Lewy bodies subjects also showed significant epicardial losses of neurofilament protein-immunoreactive nerve fibre densities within the fibre bundles as compared with cognitively normal subjects (P < 0.01) and both groups showed high pathologic alpha-synuclein densities (P < 0.0001). Cardiac alpha-synuclein densities correlated significantly with brain alpha-synuclein (P < 0.001), while cardiac tyrosine hydroxylase and neurofilament immunoreactive nerve fibre densities were negatively correlated with the densities of both brain and cardiac alpha-synuclein, as well as Unified Parkinson’s Disease Rating Scale scores (P < 0.05). The clear separation of Alzheimer’s disease/dementia with Lewy bodies subjects from Alzheimer’s disease and cognitively normal, based on cardiac tyrosine hydroxylase fibre density, is the first report of a statistically significant difference between these groups. Our data do not show significant sympathetic cardiac denervation in Alzheimer’s disease with Lewy bodies, but strongly confirm that cardiac nuclear imaging with a noradrenergic radioligand is worthy of further study as a potential means to separate Alzheimer’s disease from Alzheimer’s disease/dementia with Lewy bodies during life.
Advancing patient age is associated with worse outcomes in low‐ and intermediate‐grade primary chondrosarcoma of the pelvis
Houdek, Matthew T. , Witten, Brent G., Wenger, Doris E. , Sim, Franklin H. , Rose, Peter S. , Houdek, Matthew T , Hevesi, Mario , Griffin, Anthony M. , Salduz, Ahmet , Ferguson, Peter C. , Wunder, Jay S.

Mayo Clinic

Journal of Surgical Oncology | January 28, 2020 | Volume: 121 | Issue: 4 | Pages: 638-644

10.1002/jso.25854 | PMID 31989655 Get It

AbstractBackgroundConventional primary pelvic chondrosarcoma often presents as a low‐ or intermediate‐grade tumor in older patients. Although this is the most common variant of pelvic chondrosarcoma, studies examining treatment outcomes are lacking. The purpose of this study was to evaluate patients with these tumors to determine their outcomes of treatment.MethodsSeventy‐three patients (grade I [n = 19, 26%] and grade II [n = 54, 74%]) were reviewed including 55 (75%) males and 18 (25%) females, with a mean age of 51 (range, 17‐81) years and follow‐up of 9 ± 5 years.ResultsThe 10‐year disease‐specific survival was 71%. Grade II disease (hazard ratio [HR], 6.74; P = .04) and age ≥50 years (HR, 3.97; P = .02) was associated with death due to disease. The 10‐year local recurrence‐ and metastatic‐free survival were 79% and 72%. Of the patients with a local recurrence (n = 11), 7 (64%) recurred at a higher histological grade. Patient age ≥50 years was associated with local recurrence (HR, 10.03; P = .02) and metastatic disease (HR, 4.20; P = .02).ConclusionAdvancing patient age was an independent risk factor for worse survival and disease recurrence. Tumors often recurred locally at a higher grade and as such wide local excision remains the treatment of choice for these tumors.
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia
Pagel, John M. , Garcia‐Manero, Guillermo , Fang, Min , Radich, Jerald P. , Rizzieri, David A. , Marcucci, Guido , Strickland, Stephen A. , Litzow, Mark R. , Savoie, Mary Lynn , Confer, Dennis L. , Chell, Jeffrey W., Brown, Maria, Medeiros, Bruno C. , Lin, Tara L. , Uy, Geoffrey L. , Powell, Bayard L., Bayer, Ruthee-Lu , Stone, Richard M. , Claxton, David F. , Essell, James , Luger, Selina M. , Moseley, Anna , Appelbaum, Frederick R. , Strickland, Stephen Anthony , Claxton, David F , Lin, Tara L , Uy, Geoffrey , Othus, Megan , Spellman, Stephen R. , Sekeres, Mikkael A. , Larson, Richard A. , Mohan, Sanjay , Erba, Harry Paul

Mayo Clinic

JCO Oncology Practice | January 27, 2020 | Volume: 16 | Issue: 6 | Pages: No page available

10.1200/jop.19.00133 | PMID 32048933 Get It

PURPOSE: Patients with acute myeloid leukemia with high-risk cytogenetics in first complete remission (CR1) achieve better outcomes if they undergo allogeneic hematopoietic cell transplantation (HCT) compared with consolidation chemotherapy alone. However, only approximately 40% of such patients typically proceed to HCT. METHODS: We used a prospective organized approach to rapidly identify donors to improve the allogeneic HCT rate in adults with high-risk acute myeloid leukemia in CR1. Newly diagnosed patients had cytogenetics obtained at enrollment, and those with high-risk cytogenetics underwent expedited HLA typing and were encouraged to be referred for consultation with a transplantation team with the goal of conducting an allogeneic HCT in CR1. RESULTS: Of 738 eligible patients (median age, 49 years; range, 18-60 years of age), 159 (22%) had high-risk cytogenetics and 107 of these patients (67%) achieved CR1. Seventy (65%) of the high-risk patients underwent transplantation in CR1 ( P < .001 compared with the historical rate of 40%). Median time to HCT from CR1 was 77 days (range, 20-356 days). In landmark analysis, overall survival (OS) among patients who underwent transplantation was significantly better compared with that of patients who did not undergo transplantation (2-year OS, 48% v 35%, respectively [ P = .031]). Median relapse-free survival after transplantation in the high-risk cohort who underwent transplantation in CR1 (n = 70) was 11.5 months (range, 4-47 months), and median OS after transplantation was 14 months (range, 4-44 months). CONCLUSION: Early cytogenetic testing with an organized effort to identify a suitable allogeneic HCT donor led to a CR1 transplantation rate of 65% in the high-risk group, which, in turn, led to an improvement in OS when compared with the OS of patients who did not undergo transplantation.
Automated Quantitative Immunochemical Analysis of Human Immunoglobulins
Markowitz, Harold, Tschida, Anthony R.

Mayo Clinic

Clinical Chemistry | January 21, 2020 | Volume: 18 | Issue: 11 | Pages: 1364-1367

10.1093/clinchem/18.11.1364 Get It

Abstract A commercial automated continuous-flow procedure for estimating specific serum proteins has been evaluated for use in determination of IgG, IgA, IgM (both 19S and 7S), α1-antitrypsin, and cerebrospinal fluid proteins. Results of the automated procedure correlate well with manual methods, but are much more precise. Estimation of 7S IgM by the automated method is more accurate than estimation by radial immunodiffusion, because concentrations of 7S IgM are not spuriously elevated.
Detection of Interrupted Bubble Flow in the Technicon Automated Immunoprecipitin System
Hansen, Robert J., Tschida, Anthony R., Markowitz, Harold

Mayo Clinic

Clinical Chemistry | January 21, 2020 | Volume: 18 | Issue: 7 | Pages: 677-678

10.1093/clinchem/18.7.677 Get It

Abstract A simple unit is described for detecting interrupted flow in an automated immunoprecipitin system. The principle involved is conductivity change resulting from interruption of bubble flow.
Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer
Dancy, Jimena G. , Wadajkar, Aniket S. , Connolly, Nina P. , Galisteo, Rebeca , Ames, Heather M. , Peng, Sen, Tran, Nhan L. , Goloubeva, Olga, Woodworth, Graeme F., Winkles, Jeffrey A. , Kim, Anthony J. , Winkles, Jeffrey A , Tran, Nhan L , Woodworth, Graeme F

Mayo Clinic

Science Advances | January 16, 2020 | Volume: 6 | Issue: 3 | Pages: No page available

10.1126/sciadv.aax3931 | PMID 31998833 Get It

DART nanoparticles overcome critical drug delivery barriers for primary tumors and brain metastases.
Head and Neck Mesenchymal Neoplasms With GLI1 Gene Alterations
Xu, Bin , Chang, Koping , Folpe, Andrew L. , Kao, Yu‐Chien , Wey, Shiuan-Li, Huang, Hsuan-Ying, Gill, Anthony J. , Wey, Shiuan-Li, Rooper, Lisa M. , Bishop, Justin A. , Dickson, Brendan C. , Lee, Jen‐Chieh , Antonescu, Cristina R.

Mayo Clinic

American Journal of Surgical Pathology | January 14, 2020 | Volume: 44 | Issue: 6 | Pages: 729-737

10.1097/pas.0000000000001439 | PMID 31934916 Get It

Soft tissue tumors with GLI1 gene fusions or amplifications have been recently described as a unique pathologic entity with an established risk of malignancy. We herein expand these findings by investigating a cohort of 11 head and neck lesions with GLI1 alterations, including 8 from the tongue, for their clinicopathologic and molecular features. The tumors commonly affected males in their 30s (male:female ratio 2.7:1; range: 1 to 65). Tumors showed a multinodular growth pattern, nested architecture separated by a delicate, arborizing vascular network, monotonous round to ovoid nuclei, and clear cytoplasm. Tumor protrusion into vascular spaces was common. Genetic alterations were investigated by fluorescence in situ hybridization and/or targeted RNA sequencing. Seven tumors harbored GLI1 fusions with the following partners: ACTB (n=4), PTCH1 (n=2), or MALAT1 (n=1). The remaining 4 cases showed coamplifications of GLI1 with CDK4 and MDM2 genes. Tumors were commonly positive for S100 protein and CD56. CDK4, MDM2, and STAT6 were positive in GLI1 -amplified tumors. Two of 6 patients with available follow-up (1 each with GLI1 amplification and PTCH1-GLI1 fusion) developed distant metastases. Both tumors showed a high mitotic index and tumor necrosis. The head and neck region, particularly tongue, is a common location for GLI1 -related mesenchymal tumors. Although a morphologic overlap was noted with the previously reported “pericytoma with t(7,12) translocation,” often occurring in the tongue, our findings expand the original findings, to include a more variable immunophenotype, propensity for late distant metastases, and alternative mechanisms of GLI1 oncogenic activation, such as various GLI1 fusion partners or GLI1 coamplifications with MDM2 and CDK4 genes.
Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer’s Disease Neuropathological Changes
Buciuc, Marina , Wennberg, Alexandra , Weigand, Stephen D. , Murray, Melissa E. , Senjem, Matthew L. , Spychalla, Anthony J., Jack, Clifford R. , Kantarci, Kejal , Parisi, Joseph E., Petersen, Ronald C. , Whitwell, Jennifer L. , Josephs, Keith A. , Wennberg, Alexandra M, Jack, Clifford R , Wennberg, Alexandra M V , Buciuc, Marina , Senjem, Matthew L , Kantarci, Kejal , Murray, Melissa E , Boeve, Bradley F. , Knopman, David S. , Dickson, Dennis W.

Mayo Clinic

Journal of Alzheimer’s Disease | January 10, 2020 | Volume: 73 | Issue: 4 | Pages: 1511-1523

10.3233/jad-191040 | PMID 31929165 Get It

Background: Transactive response DNA-binding protein of 43 kDa (TDP-43) is associated with hippocampal atrophy in Alzheimer’s disease (AD), but whether the association is modified by other factors is unknown. Objective: To evaluate whether the associations between TDP-43 and hippocampal volume and atrophy rate are affected by age, gender, apolipoprotein E ( APOE) ɛ4, Lewy bodies (LBs), amyloid-β (Aβ), or Braak neurofibrillary tangle (NFT) stage. Methods: In this longitudinal neuroimaging-clinicopathological study of 468 cases with AD neuropathological changes (Aβ-positive) that had completed antemortem head MRI, we investigated how age, gender, APOE ɛ4, presence of LBs, Aβ, TDP-43, and Braak NFT stages are associated with hippocampal volumes and rates of atrophy over time. We included field strength in the models since our cohort included 1.5T and 3T scans. We then determined whether the associations between hippocampal atrophy and TDP-43 are modified by these factors using mixed effects models. Results: Older age, female gender, APOE ɛ4, higher field strength, higher TDP-43, and Braak NFT stages were associated with smaller hippocampi. Rate of atrophy was greater with higher TDP-43 and Braak NFT stage, but lower in older patients. The association of TDP-43 with greater rate of atrophy was enhanced in APOE ɛ4 carriers ( p = 0.04). Conclusion: Neurodegenerative effects of TDP-43 seem to be independent of most factors except perhaps APOE in cases with AD neuropathological changes. TDP-43 and tau appear to behave independently of one another.